Royalty launches $6.6B acquisition bid for Elan

02/26/2013 | Reuters · American City Business Journals

Royalty Pharma could buy Irish drugmaker Elan for $6.6 billion. The investment firm is interested in the royalty rights to multiple sclerosis drug Tysabri. The bid follows Elan's announcement that it would sell its half stake in Tysabri to partner Biogen Idec for $3.25 billion and royalties.

View Full Article in:

Reuters · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care